Relatlimab for Tumors
This trial is testing a new combination drug treatment for patients with MSI-H solid tumors who have not responded to other PD-(L)1 treatments.
- Microsatellite Instability-High Tumors
- Microsatellite Instability-High Solid Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is Nivolumab a danger to people when used as directed?
"While there is some data supporting Nivolumab's safety, it is only from a Phase 2 trial, so it received a score of 2."
Have similar investigations been conducted before this one?
"749 clinical trials for Nivolumab are ongoing in 2348 cities across 50 nations. The first study began a decade ago in 2010 and, after completing Phase 1 drug approval, ended with 127 participants. To date, 249 similar studies have been completed."
Are there other investigational treatments that use Nivolumab?
"At the moment, there are 749 different clinical trials ongoing that involve the use of Nivolumab. Out of those, 82 have reached Phase 3. The great majority of these studies are based in Zürich, BE; however, there are 40408 total locations running Nivolumab trials."
How many people fit the requirements to participate in this clinical trial?
"Yes, according to the listing on clinicaltrials.gov, this trial is still looking for patients. The study was first posted on November 16th, 2018 and was most recently updated on August 30th, 2020. They are currently 42 participants needed from 1 site."
Are new enrollees still being sought for this program?
"That is correct, the information hosted on clinicaltrials.gov does state that this particular trial is currently looking for patients to enroll. The date the trial was first posted was November 16th, 2018 with the most recent edit being made on August 30th, 2022. They are only 42 participants needed at a single location."